The medicine price regulator, the National Pharmaceutical Pricing Authority (NPPA), has found a price fixing mechanism suggested by its parent ministry, chemicals and fertilisers, has failed to meaningfully lower the prices of key cancer medicines.

A group of ministers (GoM) headed by agriculture minister Sharad Pawar is expected to meet soon to finalise a pricing policy on drugs.

Tuesday's meeting to examine the pricing policy prepared by ministry of chemicals & fertilisers

On Tuesday, a group of ministers (GoM) led by agriculture minister Sharad Pawar will examine the proposed National Pharmaceutical Pricing Policy (NPPP) prepared by the ministry of chemicals and fertilisers.

A high-level panel constituted by the health ministry is likely to suggest a system of negotiated prices for all new medicines approved in the country. The proposal to control the launch prices of drugs comes at a time when the chemicals and fertilisers ministry, responsible for deciding medicine prices, is busy preparing a national pharmaceutical pricing policy covering all essential medicines.

The central government’s plans to introduce a new rule under the existing Drugs and Cosmetics Act to compensate clinical trial victims has been challenged before the Lucknow bench of the Allahabad

Wants to take control of medicine price regulator from the chemicals ministry.

The health ministry is planning to develop a foolproof mechanism to ensure recall of all faulty and banned drugs from the Rs 60,000-crore domestic pharmaceutical market.

Even as India’s largest drug maker, Ranbaxy, is confident of launching its first “new drug” by January 2012 to combat malaria in the country, the global euphoria the potential drug had generated in

The global meltdown has started to hurt India

Drug-maker filed response in US court yesterday. Under fire in the United States for giving distorted information on the generic drugs it sold, Ranbaxy Laboratories today said that it will file all relevant information within a month after which the legal case initiated against it by the US government will be withdrawn. This is a key disclosure in the response filed by Ranbaxy in a district court in Maryland yesterday against the "motion to compel" filed by the US government on July 3.